1.	A Study of IMC-3G3 in Soft Tissue Sarcoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14055, I5B-IE-JGDG, CP15-0806, NCT01185964
2.	A Phase I/II Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents Phase: Phase II, Phase I Type: Supportive care Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: KDX1101, NCT01596088
3.	Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults Phase: Phase II Type: Treatment Status: Active Age: 40 and under Sponsor: Other Protocol IDs: GEIS-21, 2009-016027-62, NCT01696669
4.	Phase I Study of Obatoclax Mesylate in Combination With Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Pediatric Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia Phase: Phase I Type: Treatment Status: Active Age: 6 months to 21 years Sponsor: NCI Protocol IDs: COG-ADVL0816, ADVL0816, NCT00933985
5.	Phase I Study of Crizotinib and Combination Chemotherapy in Treating Pediatric Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 13 months to 21 years Sponsor: NCI Protocol IDs: COG-ADVL1212, ADVL1212, NCT01606878